- Trials with a EudraCT protocol (192)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (57)
192 result(s) found for: Factor V.
Displaying page 1 of 10.
EudraCT Number: 2015-002866-21 | Sponsor Protocol Number: BH29884 | Start Date*: 2016-01-11 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS ... | ||||||||||||||||||
Medical condition: Hemophilia A with Inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000973-38 | Sponsor Protocol Number: 14-026 | Start Date*: 2014-05-14 |
Sponsor Name:RWTH Aachen vertreten durch das CTC-A | ||
Full Title: Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-002613-30 | Sponsor Protocol Number: GH-3899 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 12-month, open-labelled, randomised, parallel-group, multi-centre, interventional trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) ther... | |||||||||||||
Medical condition: Idiopathic short stature | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000883-27 | Sponsor Protocol Number: Rif_CVID_260611 | Start Date*: 2013-08-16 |
Sponsor Name:Oslo University hospital | ||
Full Title: EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL | ||
Medical condition: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021196-85 | Sponsor Protocol Number: BNIT-PRV-301 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Bavarian Nordic, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer | |||||||||||||
Medical condition: Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) EE (Prematurely Ended) IS (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002686-36 | Sponsor Protocol Number: 20053 | Start Date*: 2005-09-19 |
Sponsor Name:Všeobecná fakultní nemocnice v Praze | ||
Full Title: Developmental pharmacokinetics and pharmacogenetics aspects of analgosedation by tramadol of newborns, infants and older children treated at the intensive care unit | ||
Medical condition: children requiring analgosedation with tramadol | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000284-21 | Sponsor Protocol Number: 524E-CVD-9101-004 | Start Date*: 2007-11-08 | |||||||||||
Sponsor Name:York Hospitals NHS Foundation Trust [...] | |||||||||||||
Full Title: A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women | |||||||||||||
Medical condition: Thrombophilia in pregnancy. This is a multi-centre, multi-national randomised controlled trial of Low Molecular Weight Heparin to prevent pregnancy complications in high-risk pregnant thrombophi... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000644-25 | Sponsor Protocol Number: INSM-110-303 | Start Date*: 2004-07-09 |
Sponsor Name:Insmed Incorporated | ||
Full Title: A Phase II/III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3), Admini... | ||
Medical condition: Growth Hormone Insensitivity Syndrome (GHIS) is a genetically disturbance of the biological action of growth hormone (GH). This study is intended to evaluate the ability of rhIGF-I/rhIGFBP-3 to de... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SK (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014580-39 | Sponsor Protocol Number: SP-B-02 | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:ALK-Abelló Arzneimittel GmbH | |||||||||||||
Full Title: A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch | |||||||||||||
Medical condition: Birch pollen induced allergic rhinoconjunctivitis requiring treatment during the birch pollen season | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006728-73 | Sponsor Protocol Number: GENOM-008 | Start Date*: 2009-03-09 |
Sponsor Name:GRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA | ||
Full Title: Ensayo Clínico abierto, fase II, de tratamiento neo-adyuvante de Sunitinib (SU11248) previo al tratamiento con irradiación y concomitante a la misma, en pacientes con Glioblastoma RPA-V-VI y sólo b... | ||
Medical condition: Glioblastoma clase RPA V-VI, no resecable | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014448-13 | Sponsor Protocol Number: 113572 | Start Date*: 2009-09-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, randomised, single-blind study to evaluate the immunogenicity and safety of sequential administration of a licensed seasonal trivalent vaccine and the pandemic H1N1 influenza candidate... | ||
Medical condition: Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 61 years or above. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001074-15 | Sponsor Protocol Number: GEN701 | Start Date*: 2013-10-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Genmab A/S | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: First-in-human, dose-escalating safety study of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors kno... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (n... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022660-12 | Sponsor Protocol Number: PRAISE_ZKS0006 | Start Date*: 2011-02-02 | |||||||||||
Sponsor Name:Friedrich Schiller University | |||||||||||||
Full Title: A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation | |||||||||||||
Medical condition: the early postoperative period after liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001648-24 | Sponsor Protocol Number: MedOPP321_ABIGAIL | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:MEDICA SCIENTIA INNOVATION RESEARCH S.L. | |||||||||||||
Full Title: randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as f... | |||||||||||||
Medical condition: Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease crite... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003512-23 | Sponsor Protocol Number: 114495 | Start Date*: 2015-06-03 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase II, randomized, observer blind, multicenter study to evaluate the safety and immunogenicity of a single low dose of AS03-adjuvanted, Quebec- or Dresden- manufactured monovalent A/California... | ||||||||||||||||||
Medical condition: Healthy volunteers (immunization against A/California/7/2009 (H1N1)v-like influenza) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001657-28 | Sponsor Protocol Number: CTHC002 | Start Date*: 2014-01-23 | |||||||||||
Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz | |||||||||||||
Full Title: Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE) | |||||||||||||
Medical condition: Acute low-risk pulmonary embolism (PE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) FI (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023139-40 | Sponsor Protocol Number: CD-2010-01 | Start Date*: 2012-10-29 |
Sponsor Name:Instituto Científico y Tecnológico de Navarra | ||
Full Title: Estudio fase II con inmunoterapia mediante células dendríticas e Hiltonol en pacientes con tumores sólidos. | ||
Medical condition: Tumores sólidos avanzados, no susceptibles de tratamiento convencional. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001813-18 | Sponsor Protocol Number: AOI_2019_JABAUDON | Start Date*: 2020-07-29 |
Sponsor Name:CHU de CLERMONT-FERRAND | ||
Full Title: Randomized Clinical Trial of Inhaled Sedation with Sevoflurane in Critically Ill Patients at Risk of Developing the Acute Respiratory Distress Syndrome | ||
Medical condition: Patients in ICU with risks of Acute Respiratory Distress Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000773-31 | Sponsor Protocol Number: E7050-702 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Eisai Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head an... | |||||||||||||
Medical condition: Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005182-14 | Sponsor Protocol Number: A-20-1013-C-03 | Start Date*: 2021-02-25 | |||||||||||
Sponsor Name:Alligator Bioscience AB | |||||||||||||
Full Title: An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma | |||||||||||||
Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
